CMMB Q4 2019 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$10M

Net Income

$15M

EPS (Diluted)

$19.58

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$13M

Total Liabilities

$787,000

Stockholders' Equity

$12M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$19,864	+100.0%
Operating Income	-$10M	-$3M	-253.7%
Net Income	$15M	-$2M	+920.3%